Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone

American Journal of Hypertension

Volumn 13, Issue 1 II SUPPL., 2000, Pages 74-82

  Benson, Steve ^a   Wu, Jenny ^a   Padmanabhan, Swathi ^a   Kurtz, Theodore W ^a,b   Pershadsingh, Harrihar A ^b,c,d  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KERN MEDICAL CENTER   (United States)

Author keywords

Migration; Peroxisome proliferator activated receptor ; Proliferation; Thiazolidinedione; Troglitazone; Vascular smooth muscle

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; TROGLITAZONE;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; DNA SYNTHESIS INHIBITION; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE;

BLOTTING, NORTHERN; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CHEMOTAXIS; CHROMANS; CORONARY VESSELS; DNA; DNA-BINDING PROTEINS; GENES, FOS; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASODILATOR AGENTS;

EID: 0033976813     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00148-x     Document Type: Article

References (50)

1. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Ross R: Cell biology of atherosclerosis. Annu Rev Physiol 1995;57:791-804.
3. Owens GK, Vernon SM, Madsen CS: Molecular regulation of smooth muscle cell differentiation. J Hypertension 1996;14(suppl):S55-S64.
4. Crowley ST, Ray CJ, Nawaz D, Majack RA, Horwitz LD: Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Physiol 1995;269:H1641-H1647.
5. Liu MW, Roubin GS, King SB: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-1387.
6. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Mowery J: Atherosclerosis. Potential targets for stabilization and regression. Circulation 1992; 86(6 suppl):II1117-II1123.
7. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 1997;26:553-573.
8. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995:8:316-320.
9. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994;24:170-175.
10. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M: Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 1998;123: 675-682.
11. Pershadsingh HA, Szollosi J, Benson SC, Kurtz TW: Pharmacological reversal of hyperinsulinemia is associated with a reduction in blood pressure: a novel approach to the treatment of hypertension. Hypertension 1992;20:322-324.
12. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 1993;22:1020-1023.
13. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-R732.
14. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995;96:354-360.
15. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J Biol Chem 1995;12953-12956.
17. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995;83:841-850.
18. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
19. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-366.
20. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997;272:8071-8076.
21. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA: Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10:440-446.
22. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komoda T: Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997;235:113-116.
23. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
24. Cory A, Owen T, Barltrop JA, Cory JG: Use of an aqueous tetrazolium/formazan assay for cell growth assays in culture. Cancer Comm 1991;3:207-222.
25. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC: Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50:1087-1094.
26. Treisman R: Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev 1994;4:96-101.
27. Janknecht R: Regulation of the c-fos promoter. Immunobiology 1995;193:137-142.
28. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors. Transcriptional regulators of adipogenesis, lipid metabolism, and more. Chemistry & Biology 1995;2:261-266.
29. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
30. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Toba K, Ouchi Y: Expression of peroxisome proliferator-activated receptor γ(PPARγ) in rat aortic smooth muscle cells. Biochim Biophys Res Commun 1998;247:353-356.
31. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83: 1097-1103.
32. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not PPARγ activators. Nature 1998;393;790-793.
33. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-deoxy-Δ-12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803-12.
34. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-819.
35. Xi X, Graf K, Goetze S, Hsueh WA, Law RE: Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 1997;417:283-286.
36. Rosendorff C: Vascular hypertrophy in hypertension: role of the renin-angiotensin system. Mt Sinai J Med 1998;65:108-117.
37. Mills CJ, Northrup JL, Hullinger TG, Simmons CA, Shebuski RJ, Jones DA: Temporal expression of c-fos mRNA following balloon injury in the rat common carotid artery. Cardiovasc Res 1996;32:954-966.
38. Sylvester AM, Chen D, Krasinski K, Andres V: Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. J Clin Invest 1998;101:940-948.
39. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE: Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997;29: 334-339.
40. Graf K, Xi XP, Hsueh WA, Law RE: Troglitazone inhibits angiotensin Il-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 1997; 400:119-122.
41. Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, Kameda-Takemura K, Matsuzawa Y: Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 1998;136:163-168.
42. Dolmetsch RE, Xu K, Lewis RS: Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998;392:933-936.
43. Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 1986;46:155-169.
44. Jawien A, Bowen-Pope DF, Linder V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89: 507-511.
45. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Maiden LT, Masuko H, Sato H: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990;248:1009-1012.
46. Ferns G, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-1132.
47. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997;25:320-325.
48. Parish MA, Grossi EA, Baumann FG, Asai T, Rifkin DB, Colvin SB, Galloway AC: Effects of a single administration of fibroblast growth factor on vascular wall reaction to injury. Ann Thorac Surg 1995;59:948-954.
49. Lawrence M, Watson L, Pettijohn T, Doyle T, Tasca SI, Stoica G: Immunohistochemical localization of proliferating cells, basic fibroblast growth factor and Fos protein following iliac artery balloon angioplasty in hypercholesterolemic rabbits. In Vivo 1995;9:27-34.
50. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J: Mechanisms of action of troglitazone in the prevention of high glucose induced migration and proliferation cultured coronary smooth muscle cells. Circ Res 1997;81:953-962.